Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.

Mahalingam D, Espitia CM, Medina EC, Esquivel JA 2nd, Kelly KR, Bearss D, Choy G, Taverna P, Carew JS, Giles FJ, Nawrocki ST

Open source

DOI: 10.1038/bjc.2011.426
Published: 2011 Nov 8
Container: British journal of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/bjc.2011.426,
  title = {Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.},
  author = {Mahalingam D and Espitia CM and Medina EC and Esquivel JA 2nd and Kelly KR and Bearss D and Choy G and Taverna P and Carew JS and Giles FJ and Nawrocki ST},
  year = {2011},
  journal = {British journal of cancer},
  doi = {10.1038/bjc.2011.426},
  url = {https://doi.org/10.1038/bjc.2011.426}
}

RIS

TY  - JOUR
TI  - Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.
AU  - Mahalingam D
AU  - Espitia CM
AU  - Medina EC
AU  - Esquivel JA 2nd
AU  - Kelly KR
AU  - Bearss D
AU  - Choy G
AU  - Taverna P
AU  - Carew JS
AU  - Giles FJ
AU  - Nawrocki ST
PY  - 2011
JO  - British journal of cancer
DO  - 10.1038/bjc.2011.426
UR  - https://doi.org/10.1038/bjc.2011.426
ER  -

APA

D, M., CM, E., EC, M., 2nd, E. J., KR, K., D, B., G, C., P, T., JS, C., FJ, G., & ST, N. (2011). Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.. British journal of cancer. https://doi.org/10.1038/bjc.2011.426

Source records

pubmed · retrieved 2026-09-27T12:05:35.106Z